Cover Image
市場調查報告書

肝纖維化:開發中產品分析

Liver Fibrosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213097
出版日期 內容資訊 英文 216 Pages
訂單完成後即時交付
價格
Back to Top
肝纖維化:開發中產品分析 Liver Fibrosis - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 216 Pages
簡介

肝纖維化是由於肝臟反應慢性肝臟疾病,開始形成疤痕的過程,是由於肝臟反覆受到損傷所造成的。常見有急性發炎、衰弱、黃膽等症狀。

本報告提供肝纖維化的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肝纖維化概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肝纖維化:企業開發中的治療藥

肝纖維化:大學/機關研究中的治療藥

肝纖維化:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肝纖維化:企業開發中的產品

肝纖維化:大學/機關研究中的產品

肝纖維化的治療藥的開發企業

  • Advinus Therapeutics Ltd.
  • AiCuris GmbH & Co. KG
  • Akarna Therapeutics Ltd.
  • Angion Biomedica Corp.
  • Asubio Pharma Co., Ltd.
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Bird Rock Bio, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Dicerna Pharmaceuticals, Inc.
  • Digna Biotech, S.L.
  • Dr. Falk Pharma GmbH
  • Dynavax Technologies Corporation
  • Evotec AG
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Genfit SA
  • Gilead Sciences, Inc.
  • GNI Group Ltd.
  • HEC Pharm Co., Ltd.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Isarna Therapeutics GmbH
  • KineMed, Inc.
  • LG Life Science LTD.
  • Nitto Denko Corporation
  • Pfizer Inc.
  • Pharmaxis Limited
  • Promedior, Inc.
  • Promethera Biosciences S.A.
  • ProMetic Life Sciences Inc.
  • RXi Pharmaceuticals Corporation
  • SciFluor Life Sciences, LLC
  • TCM Biotech International Corp
  • Vascular Biogenics Ltd.
  • Virobay Inc.
  • XTuit Pharmaceuticals, Inc.

肝纖維化:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肝纖維化:最近的開發平台趨勢

肝纖維化:暫停中的計劃

肝纖維化:開發中止的產品

肝纖維化:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9719IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H2 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape.

Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 7, 3, 1, 1, 51 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Liver Fibrosis - Overview
  • Liver Fibrosis - Therapeutics Development
  • Liver Fibrosis - Therapeutics Assessment
  • Liver Fibrosis - Companies Involved in Therapeutics Development
  • Liver Fibrosis - Drug Profiles
  • Liver Fibrosis - Dormant Projects
  • Liver Fibrosis - Discontinued Products
  • Liver Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Liver Fibrosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Liver Fibrosis - Pipeline by Allergan Plc, H2 2017
  • Liver Fibrosis - Pipeline by Angion Biomedica Corp, H2 2017
  • Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017
  • Liver Fibrosis - Pipeline by BioLineRx Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Bioneer Corp, H2 2017
  • Liver Fibrosis - Pipeline by BiOrion Technologies BV, H2 2017
  • Liver Fibrosis - Pipeline by Bird Rock Bio Inc, H2 2017
  • Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Liver Fibrosis - Pipeline by Cellmid Ltd, H2 2017
  • Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
  • Liver Fibrosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017
  • Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2017
  • Liver Fibrosis - Pipeline by Dynavax Technologies Corp, H2 2017
  • Liver Fibrosis - Pipeline by Evotec AG, H2 2017
  • Liver Fibrosis - Pipeline by FibroGen Inc, H2 2017
  • Liver Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017
  • Liver Fibrosis - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Genfit SA, H2 2017
  • Liver Fibrosis - Pipeline by GenKyoTex SA, H2 2017
  • Liver Fibrosis - Pipeline by GNI Group Ltd, H2 2017
  • Liver Fibrosis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Immuron Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017
  • Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017
  • Liver Fibrosis - Pipeline by KineMed Inc, H2 2017
  • Liver Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Pfizer Inc, H2 2017
  • Liver Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Promedior Inc, H2 2017
  • Liver Fibrosis - Pipeline by Promethera Biosciences SA, H2 2017
  • Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Liver Fibrosis - Pipeline by Ribomic Inc, H2 2017
  • Liver Fibrosis - Pipeline by Samumed LLC, H2 2017
  • Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2017
  • Liver Fibrosis - Pipeline by Sirnaomics Inc, H2 2017
  • Liver Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
  • Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2017
  • Liver Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
  • Liver Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2017
  • Liver Fibrosis - Pipeline by Virobay Inc, H2 2017
  • Liver Fibrosis - Dormant Projects, H2 2017
  • Liver Fibrosis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Liver Fibrosis - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Liver Fibrosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Liver Fibrosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top